

Great Lakes Pharmaceuticals, Inc. announces \$2.6 million award from National Institutes of Health

Award from NIH will advance Company's development of a novel antimicrobial catheter lock solution.

Beachwood, OH - (July 29, 2009) - Great Lakes Pharmaceuticals, Inc. announced that the Company has received a Notice of Award from the National Institutes of Health (NIH), National Heart, Lung, And Blood Institute (NHLBI) in support of the project "Development of B-Lock an antibiofilm catheter lock product". The \$2.6 million grant will support efforts to move the Company's B-Lock™, an antimicrobial catheter lock solution, forward to human clinical trial testing for the prevention of infections related to central venous catheters.

"We are proud to receive this significant grant award from NHLBI. This award will help us speed the development of B-Lock™, a solution for antimicrobial treatment of implanted catheters," said Krzysztof Appelt, PhD, Principal Investigator for the project and President and CEO of Great Lakes Pharmaceuticals, Inc. "Thanks to this support, Great Lakes Pharmaceuticals can continue its innovative approach to preventing blood stream infections in seriously ill patients with indwelled catheters and reducing the healthcare costs at the same time."